Nothing Special   »   [go: up one dir, main page]

MXPA03009586A - Ciclosporina modificada que puede ser usada como un pro-farmaco y uso de la misma. - Google Patents

Ciclosporina modificada que puede ser usada como un pro-farmaco y uso de la misma.

Info

Publication number
MXPA03009586A
MXPA03009586A MXPA03009586A MXPA03009586A MXPA03009586A MX PA03009586 A MXPA03009586 A MX PA03009586A MX PA03009586 A MXPA03009586 A MX PA03009586A MX PA03009586 A MXPA03009586 A MX PA03009586A MX PA03009586 A MXPA03009586 A MX PA03009586A
Authority
MX
Mexico
Prior art keywords
group
linear
alkyl group
carbon atoms
alkyl
Prior art date
Application number
MXPA03009586A
Other languages
English (en)
Inventor
Wenger Roland
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of MXPA03009586A publication Critical patent/MXPA03009586A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a un pro-farmaco que comprende un undecapeptido ciclico en donde la cadena del peptido del mismo comprende por lo menos un residuo de aminoacidos de la formula general (1) en donde el atomo de carbono Ca es uno de los enlaces en dicho ciclo undecapeptido; - substituyentes Y que representan individualmente un atomo de hidrogeno o forman un enlace juntos; - los substituyentes R1 y R3 representan independientemente un atomo de hidrogeno, un grupo aralquilo, un grupo alcarilo, un grupo heteroalquilo, un grupo heterociclico, un grupo alquilo heterociclico, un grupo heterociclico alquilo, o un grupo alquilo que tiene de 1 a 6 atomos de carbono el cual es recto o ramificado, y que es opcionalmente sustituido por al menos uno de los grupos seleccionados entre -COOH, -CONHR8, -NHCO=NH(NH2), -NHC=NR8(NH2), -NH2, -NHR8, -NR82, -N+R83, -OH, -OPO(OR8)2, -OPO(OH)(OR8), -OPO(OH)2, -OSO(OR8)2, -OSO(OH)(OR8), -OSO(OH)2, y las diferentes sales producidas de los mismos, representando independientemente cada uno de los substituyentes R8 un grupo alquilo el cual es recto o ramificado que tiene de 1 a 6 atomos de carbono; - los substituyentes R2 y R4 representan independientemente un atomo de hidrogeno, un grupo alcarilo o un grupo alquilo que tiene de 1 a 6 atomos de carbono el cual es recto o ramificado; - los substituyentes R5 y R6 representan individualmente un atomo de hidrogeno, un grupo aralquilo, un grupo alquilo que tiene de 1 a 6 atomos de carbono el cual es recto o ramificado; y un substituyente R7 que representa un grupo alcarilo, un grupo heteroalquilo, un grupo heterociclico, un grupo alquilo heterociclico, un grupo heterociclico alquilo o un grupo alquilo que tiene de 1 a 6 atomos de carbono el cual es recto o ramificado.
MXPA03009586A 2001-04-20 2002-04-22 Ciclosporina modificada que puede ser usada como un pro-farmaco y uso de la misma. MXPA03009586A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH7202001 2001-04-20
PCT/CH2002/000222 WO2002085928A2 (fr) 2001-04-20 2002-04-22 Cyclosporine modifiee utilisable en tant que pro-drogue et son utilisation

Publications (1)

Publication Number Publication Date
MXPA03009586A true MXPA03009586A (es) 2004-05-24

Family

ID=4531478

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009586A MXPA03009586A (es) 2001-04-20 2002-04-22 Ciclosporina modificada que puede ser usada como un pro-farmaco y uso de la misma.

Country Status (17)

Country Link
US (1) US6995139B2 (es)
EP (1) EP1379547B1 (es)
JP (1) JP4588979B2 (es)
KR (1) KR100932859B1 (es)
CN (1) CN1507451A (es)
AT (1) ATE313557T1 (es)
AU (1) AU2002245996B8 (es)
BR (1) BR0208923A (es)
CA (1) CA2444278C (es)
DE (1) DE60208180T2 (es)
ES (1) ES2256450T3 (es)
IL (1) IL158385A0 (es)
MX (1) MXPA03009586A (es)
RU (1) RU2290196C2 (es)
UA (1) UA75136C2 (es)
WO (1) WO2002085928A2 (es)
ZA (1) ZA200307794B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP1904056B1 (en) 2005-07-18 2009-04-29 Minu, L.L.C. Use of a macrolide to restore corneal sensation
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7531572B2 (en) 2006-07-28 2009-05-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
US8394763B2 (en) 2007-09-26 2013-03-12 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) * 2008-02-08 2009-08-13 Debiopharm Sa Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
RU2630690C9 (ru) 2010-12-15 2017-12-28 КонтраВир Фармасьютикалз, Инк. МОЛЕКУЛЫ АНАЛОГОВ ЦИКЛОСПОРИНА, МОДИФИЦИРОВАННЫЕ ПО 1 и 3 АМИНОКИСЛОТЕ
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
CN113388002A (zh) * 2021-06-10 2021-09-14 梯尔希(南京)药物研发有限公司 一种环孢菌素相关化合物的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396542A (en) * 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
ATE43335T1 (de) * 1980-02-14 1989-06-15 Sandoz Ag Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung.
US5169773A (en) * 1984-10-04 1992-12-08 Sandoz Ltd. Monoclonal antibodies to cyclosporins
ATE43499T1 (de) * 1984-10-10 1989-06-15 Ile De France Synergistische empfaengnisverhuetende mischung.
US4764503A (en) * 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
DK0484281T4 (da) * 1990-11-02 2001-02-05 Novartis Ag Cyclosporiner
US6187547B1 (en) * 1993-09-08 2001-02-13 Novartis Ag Assay kit
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US6017879A (en) * 1998-04-03 2000-01-25 B.M.R.A. Corporation B.V. Template associated NPY Y2-receptor agonists
DE69928938T2 (de) 1998-07-01 2006-08-17 Debiopharm S.A. Neues cyclosporin mit verbesserter wirkung
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
DE60028936T2 (de) * 1999-02-05 2007-01-11 Debiopharm S.A. Cyclosporin-derivate und verfahren zu deren herstellung
US6765019B1 (en) * 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
WO2001005819A1 (en) * 1999-07-15 2001-01-25 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
MXPA02001857A (es) * 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.

Also Published As

Publication number Publication date
DE60208180T2 (de) 2006-08-17
CA2444278C (en) 2011-11-22
KR100932859B1 (ko) 2009-12-23
EP1379547A2 (fr) 2004-01-14
ZA200307794B (en) 2004-07-19
UA75136C2 (en) 2006-03-15
AU2002245996B2 (en) 2005-06-30
JP4588979B2 (ja) 2010-12-01
IL158385A0 (en) 2004-05-12
KR20030094357A (ko) 2003-12-11
RU2003133742A (ru) 2005-03-20
CA2444278A1 (en) 2002-10-31
AU2002245996B8 (en) 2005-07-14
US20040138108A1 (en) 2004-07-15
US6995139B2 (en) 2006-02-07
CN1507451A (zh) 2004-06-23
ES2256450T3 (es) 2006-07-16
ATE313557T1 (de) 2006-01-15
EP1379547B1 (fr) 2005-12-21
JP2004536051A (ja) 2004-12-02
RU2290196C2 (ru) 2006-12-27
DE60208180D1 (de) 2006-01-26
WO2002085928A2 (fr) 2002-10-31
BR0208923A (pt) 2004-04-27
WO2002085928A3 (fr) 2003-04-17

Similar Documents

Publication Publication Date Title
MXPA03009586A (es) Ciclosporina modificada que puede ser usada como un pro-farmaco y uso de la misma.
TW200642683A (en) Heterocyclic compound
WO2008114819A1 (ja) 新規アデニン化合物
MX2009010024A (es) Nuevo compuesto de adenina.
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
TW200519088A (en) Aryl or heteroaryl amide compounds
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
CO5700733A2 (es) Acidos aminocarboxilicos sustituidos
IL174664A0 (en) Optically active amino alcohol derivatives and processes for the preparation thereof
DK1325910T3 (da) Aliphatiske nitrogenholdige femleddede ringforbindelser
HRP20120695T1 (hr) 8-supstituirani benzoazepini kao modulatori toll-u sličnog receptora
TW200722432A (en) Thiazole compounds
NZ306625A (en) Tetrahydro-pyridine compounds, their preparation, and pharmaceuticals thereof; useful as neuraminidase inhibitors
MY141789A (en) Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
TW200611687A (en) Pharmaceutical compositions used for immunosuppressant
NO20054669L (no) Substituerte kinobenzoxazinanaloger
HK1111093A1 (en) Anti-inflammatory agents
TW200745048A (en) Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors
NO20072878L (no) Antitrombotiske dobbelt inhibitorer omfattende en biotin-rest
HUP9802764A2 (hu) Guanidino-proteáz-inhibitorok
IS6452A (is) Ný tetrahýdrópýridín, framleiðsluaðferð og lyfjasamsetningar sem innihalda þau
YU43902A (sh) Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
FR2806726B1 (fr) Procede de preparation de la (2s,3r,4s)-4-hydroxyisoleucine et de ses analogues
MY136065A (en) Prodrugs to nmda receptor ligands
EA200200665A1 (ru) Новые соединения бензолсульфонамида, способ их получения и фармацевтические композиции, их содержащие

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights